Rebeca Lizeth Polina-Lugo

Rebeca Lizeth Polina-Lugo

Auto-generated profile, based on publicly available information

Rebeca Lizeth Polina-Lugo

Rheumatology Department, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2025 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
JGJesus Alberto Cardenas-de la Garza
Jesus Alberto Cardenas-de la Garza
EDEmmanuel Dominguez-Chapa
Emmanuel Dominguez-Chapa
AGAngel Kevin Garza-Elizondo
Angel Kevin Garza-Elizondo
RPRebeca L Polina-Lugo
Rebeca L Polina-Lugo
JMJose Dario Martinez
Jose Dario Martinez
DGDionicio A Galarza-Delgado
Dionicio A Galarza-Delgado
Generalized pustular psoriasis (GPP) is a potentially life-threatening rare immune-mediated disease characterized by rapid onset of erythematous plaques, sterile pustules and systemic inflammation. Spesolimab, a monoclonal antibody targeting the interleukin-36 receptor, is a novel treatment for GPP. However, GPP’s low incidence and limited evidence relating to treatment with spesolimab represents a challenge in determining its real-world efficacy. This review explores the clinical use of spesolimab in a real-world setting. We conducted a review on PubMed, SCOPUS, Embase, and ScienceDirect of case series and reports of patients with GPP treated with spesolimab. Review articles and clinical trials were excluded. From 33 articles, 62 patients with GPP were included. Age ranged from 4 to 88 years. Comorbidities were reported in 48 of the 62 patients; of these, 30 had plaque psoriasis. Spesolimab 900 mg intravenous was administered in one to four doses, depending on clinical response. The second dose was administered 1 week after the first, while the additional doses were given at variable intervals. Follow-up periods ranged from 2 weeks to 15 months. Complete GPP remission was observed in 35/62 (56%) patients, 21 of them achieving it within a week. Partial remission was defined in 27 of the 62 patients (44%). GPP recurrence after treatment was observed in seven patients. Among the 30 patients with concomitant plaque psoriasis reported, after spesolimab administration, plaque psoriasis recurrence was reported in 6 (20%) patients, 3 (10%) reported improvement and for 21 (70%), this outcome was not reported. Eight patients reported adverse effects, including laboratory abnormalities, infections and erythema multiforme. Spesolimab demonstrates a low prevalence of adverse events and clinical efficacy for GPP treatment, including in patients with comorbidities, infections and those > 75 years of age. Its effect on plaque psoriasis remains unclear.


10 March 2026 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
VCValeria Cantu-Martinez
Valeria Cantu-Martinez
MVMiguel A. Villarreal-Alarcon
Miguel A. Villarreal-Alarcon
RPRebeca L. Polina-Lugo
Rebeca L. Polina-Lugo
EDEmmanuel Dominguez-Chapa
Emmanuel Dominguez-Chapa
ABAna C. Bardan-Inchaustegui
Ana C. Bardan-Inchaustegui
RARosa I. Arvizu-Rivera
Rosa I. Arvizu-Rivera

20 May 2024 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
ACAnahí Carrazco-Chapa
Anahí Carrazco-Chapa
LPLorena Perez-Barbosa
Lorena Perez-Barbosa
JGJesus Alberto Cardenas-de la Garza
Jesus Alberto Cardenas-de la Garza
DRDixon Javier Ramos-Suque
Dixon Javier Ramos-Suque
RPRebeca Lizeth Polina-Lugo
Rebeca Lizeth Polina-Lugo
CSCassandra Michele Skinner-Taylor
Cassandra Michele Skinner-Taylor